Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Ever since Frederiksen took office in Denmark in 2019, the second woman and youngest person ever to become prime minister in ...

Terry Smith slammed two of Denmark’s largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

This month, the Danish prime minister Mette Frederiksen takes up her presidency of the EU – and the timing could not be more ...

Novo Nordisk (NYSE:NVO) engages in the research & development, manufacture, and distribution of pharmaceutical products internationally. It has 2 segments: Diabetes & Obesity Care and Rare Disease.

On this news, Novo Nordisk’s stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors. Contact Us To Participate or Learn More: ...

Novo Nordisk has launched its anti-obesity drug Wegovy in India, aimed at long-term weight management and reducing cardiovascular risk. The company targets large-scale distribution, aiming to become a ...

Year to date, Novo Nordisk shares have lost 18.9% compared with the industry ’s 2.7% decline. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen ...

Novo Nordisk has terminated its short-lived collaboration with telehealth company Hims & Hers, a decision that led to a more than 30% drop in the U.S. firm's shares. The split occurred amidst conflict ...

When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk’s NovoCare Pharmacy for a discounted price of $499 per ...

Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker ...